TSI Completes Phase 1 Clinical Trial of Novel Clot-dissolving Therapy, TS01 | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.
MENU

TSI Completes Phase 1 Clinical Trial of Novel Clot-dissolving Therapy, TS01

TSI Completes Phase 1 Clinical Trial of Novel Clot-dissolving Therapy, TS01
Peptide News from Biotech and Pharma, Raw News September 19, 2017

CAMBRIDGE, MA, USA I September 18, 2017 I Thrombolytic Science, LLC (TSI), a clinical stage vascular health and biotechnology company, today ...

Email

support@boulderpeptide.org

s2Member®
loading...